The market for point-of-care (POC) testing includes clinical
chemistry, blood gas, urinalysis and blood glucose segments. Analyzers for this
market come in the form of either handheld instruments or compact benchtop
systems that are placed in critical care units of hospitals or in POLs and
individual clinics. Reagents are available in the form of cartridges, test
strips or discs.
The implementation of the Affordable Care Act (ACA) and its emphasis
on preventative and outcomes-based health care will provide an impetus to POC
testing, because the immediate availability of results during patient visits
enables physicians and other health care providers to deliver appropriate and
timely care for patients, thereby reducing delays and avoiding redundancies.
Further, as the individual physician clinics continue to consolidate to form
group practice networks and as awareness grows about the long term cost-savings
of in-house testing vis-a-vis outsourcing to reference labs, the unit sales of
POC analyzers and reagents is expected to see a steady growth.
In 2015 Abbott Diagnostics pulled out ahead as the market leader
overall, but was very closely followed by Roche Diagnostics. However, many
other companies have an impact in this market including Alfa Wassermann,
Siemens Healthcare Diagnostics, Instrumentation Laboratory, Radiometer,
Carolina Liquid Chemistry and Elitech Group to name a few.
This Report Also Includes:
- In-depth, Professionally Researched Data That Has Been Formatted and Analyzed to Gain Actionable Insights as Quickly as Possible
- Executive Summary
- Trend Analysis by Segment
- Market Value Forecasts until 2022 and History Back to 2012
- Market Drivers and Limiters
- Detailed Competitive Analysis for Each Market and Segment
To Get The Most of this report:
Combine it with our other US market reports on, Hematology,
Hemostasis, Molecular Diagnostics, Blood Donor Screening, or Point of Care
Diagnostic Devices.
Research Methodology – By utilizing a 9-Step Methodology we can ensure
that we have the most accurate, up-to-date, and representative figures of the
markets. Our data is collected with careful secondary research, and even more
importantly our primary research, gathered through interviews and
questionnaires with industry professionals, allows us the ability to perform
analysis far beyond the initial numbers.
To see sample pages or to review our research methodology in more
detail, please request it from your sales representative.
The implementation of the Affordable Care Act (ACA) and its emphasis
on preventative and outcomes-based health care will provide an impetus to POC
testing, because the immediate availability of results during patient visits
enables physicians and other health care providers to deliver appropriate and
timely care for patients, thereby reducing delays and avoiding redundancies.
Further, as the individual physician clinics continue to consolidate to form
group practice networks and as awareness grows about the long term cost-savings
of in-house testing vis-a-vis outsourcing to reference labs, the unit sales of
POC analyzers and reagents is expected to see a steady growth.
Spanning over 80 pages “US
Market for Point of Care Diagnostic Devices - 2016 (Forecasted to 2022)” report
covers Executive Summary, Research Methodology, Point Of Care Diagnostic Device
Market. The report covered companies few are - Abbott Diagnostics,
Roche Diagnostics, Alfa Wassermann, Siemens Healthcare Diagnostics,
Instrumentation Laboratory, Radiometer, Carolina Liquid Chemistry, Elitech
Group, Nova Biomedical, Horiba, ARKRAY USA Inc., Awareness Technolo
For
further information on this report, please visit- http://mrr.cm/oWm
Find
all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare
No comments:
Post a Comment
Note: only a member of this blog may post a comment.